Inflamm Res. 2026 Jul 1;75(1):163. doi: 10.1007/s00011-026-02319-1.
ABSTRACT
This commentary provides a critical appraisal of the recent study by Chen and colleagues, which demonstrated that cutaneous palmitic acid (PA) aggravates atopic dermatitis (AD) by driving S-palmitoylation of transient receptor potential vanilloid 1 (TRPV1) in sensory neurons and Mas-related G protein-coupled receptor B2 (MRGPRB2) in mast cells, with the serum/glucocorticoid regulated kinase 1 (SGK1)/neural precursor cell expressed developmentally downregulated protein 4-like (NEDD4L) axis serving as a critical contextual regulator. While the original study offers compelling in vivo genetic validation, several mechanistic and translational questions remain unresolved. Here, we prioritize three areas for future investigation: first, the upstream sources of elevated cutaneous PA-whether derived from keratinocyte lipogenesis, systemic circulation, or microbial production-remain undefined and warrant cell-type-specific genetic interrogation complemented by stable-isotope tracing, spatial lipidomics, and germ-free models. Second, the functional divergence of S-palmitoylation on TRPV1 (promoting degradation) versus MRGPRB2 (conferring stabilization) suggests involvement of distinct palmitoyl acyltransferases (PATs) or context-dependent effects; we propose testable hypotheses including the candidate PAT zDHHC4 for TRPV1 and advocate for cell-based reconstitution, cysteine-mutant rescue, and PAT screening approaches. Third, the anatomical divergence in spinal inflammation between nape and ear models raises questions about the generalizability of central neuroimmune engagement across AD phenotypes, with implications for preclinical model selection and clinical subset stratification. Addressing these questions will clarify whether the PA-palmitoylation-neuroimmune axis represents a tractable therapeutic target and will inform the development of precision interventions that interrupt this pathway without disrupting broader homeostatic palmitoylation, while recognizing that current lack of cell-type-specific palmitoylation inhibitors remains a major hurdle.
PMID:42384050 | DOI:10.1007/s00011-026-02319-1